StageZero Life Sciences Ltd (TO:SZLS) — Stock Price
StageZero Life Sciences Ltd (TO:SZLS) is currently trading at CA$0.04 CAD, up 0.00% today. Over the past 52 weeks, shares have ranged between CA$0.04 and CA$0.04. This page tracks StageZero Life Sciences Ltd's live share price on the TO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see SZLS stock market capitalisation.
StageZero Life Sciences Ltd (SZLS) Stock Price Chart — Daily History & Trading Volume
The chart below tracks StageZero Life Sciences Ltd's daily closing share price and trading volume on the TO exchange over the past year, giving a clear view of recent price momentum and liquidity.
StageZero Life Sciences Ltd Income Statement — Revenue, Profit & Earnings by Year
StageZero Life Sciences Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Total Revenue | CA$2.88 Million | CA$3.80 Million | CA$5.07 Million | CA$4.15 Million | CA$138.70K |
| Cost of Revenue | CA$2.87 Million | CA$4.20 Million | CA$3.89 Million | CA$3.46 Million | CA$1.10 Million |
| Gross Profit | CA$10.35K | CA$-403.75K | CA$1.18 Million | CA$695.55K | CA$-960.91K |
| Research & Development | CA$95.89K | CA$351.99K | CA$774.54K | CA$218.70K | — |
| SG&A | CA$4.12 Million | CA$5.91 Million | CA$6.98 Million | CA$4.02 Million | CA$4.18 Million |
| Total Operating Expenses | CA$7.49 Million | CA$7.34 Million | CA$9.31 Million | CA$4.05 Million | CA$4.18 Million |
| Operating Income | CA$-4.61 Million | CA$-7.75 Million | CA$-8.13 Million | CA$-3.70 Million | CA$-5.11 Million |
| EBITDA | — | CA$-10.76 Million | CA$-7.62 Million | CA$-3.48 Million | CA$-4.81 Million |
| EBIT | — | CA$-11.20 Million | CA$-8.13 Million | CA$-3.70 Million | CA$-5.11 Million |
| Interest Expense | CA$325.35K | CA$284.07K | CA$200.31K | CA$320.42K | CA$803.20K |
| Income Before Tax | CA$-12.53 Million | CA$-11.42 Million | CA$-7.48 Million | CA$-6.86 Million | CA$-3.48 Million |
| Income Tax Expense | — | CA$3.30 Million | CA$200.31K | CA$320.42K | CA$830.49K |
| Net Income | CA$-12.53 Million | CA$-11.42 Million | CA$-7.68 Million | CA$-7.18 Million | CA$-4.31 Million |
StageZero Life Sciences Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes StageZero Life Sciences Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Total Assets | CA$700.65K | CA$10.65 Million | CA$8.51 Million | CA$1.96 Million | CA$2.49 Million |
| Total Current Assets | CA$266.21K | CA$2.39 Million | CA$7.22 Million | CA$226.88K | CA$352.90K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | CA$31.24K | CA$126.90K | CA$170.07K | CA$21.70K | CA$45.10K |
| Inventory | CA$95.62K | CA$408.80K | CA$355.00K | CA$87.74K | CA$110.96K |
| Property, Plant & Equipment | CA$434.44K | CA$871.89K | CA$1.26 Million | CA$1.04 Million | CA$1.07 Million |
| Goodwill | CA$0.00 | CA$7.36 Million | CA$0.00 | — | CA$1.04 Million |
| Total Liabilities | CA$8.20 Million | CA$7.88 Million | CA$9.74 Million | CA$6.46 Million | CA$7.32 Million |
| Total Current Liabilities | CA$7.03 Million | CA$4.74 Million | CA$5.59 Million | CA$4.22 Million | CA$5.52 Million |
| Long-term Debt | CA$576.38K | CA$582.46K | CA$551.49K | CA$572.53K | CA$954.33K |
| Net Debt | CA$1.78 Million | CA$-368.50K | CA$-3.03 Million | CA$2.39 Million | CA$3.12 Million |
| Total Stockholder Equity | CA$-7.50 Million | CA$2.76 Million | CA$-1.23 Million | CA$-4.49 Million | CA$-4.84 Million |
| Retained Earnings | CA$-123.04 Million | CA$-111.62 Million | CA$-104.14 Million | CA$-97.28 Million | CA$-93.60 Million |
StageZero Life Sciences Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how StageZero Life Sciences Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | CA$-809.15K | CA$-3.53 Million | CA$-8.95 Million | CA$-3.06 Million | CA$-4.59 Million |
| Capital Expenditures | CA$0.00 | CA$0.00 | CA$148.22K | CA$72.32K | CA$44.38K |
| Free Cash Flow | CA$-809.15K | CA$-3.53 Million | CA$-9.10 Million | CA$-3.14 Million | CA$-4.64 Million |
| Investing Cash Flow | — | CA$0.00 | CA$-20.96K | CA$-72.32K | CA$-33.38K |
| Financing Cash Flow | CA$813.00K | CA$1.83 Million | CA$4.10 Million | CA$9.66 Million | CA$4.59 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | CA$629.92K | CA$238.51K | CA$390.94K | CA$636.74K | CA$741.45K |
| Depreciation | CA$283.01K | CA$437.45K | CA$509.27K | CA$216.33K | CA$298.09K |
| Change in Cash | CA$-9.16K | CA$-1.71 Million | CA$-4.87 Million | CA$6.53 Million | CA$-35.10K |
StageZero Life Sciences Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track StageZero Life Sciences Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 15, 2025 | — | — | — |
| Sep 29, 2025 | — | — | — |
| Jun 04, 2025 | — | — | — |
| Nov 29, 2024 | 0.00 | — | — |
| Aug 13, 2024 | -0.01 | — | — |
| May 30, 2024 | 0.00 | — | — |
| Nov 14, 2023 | -0.01 | — | — |
| Aug 15, 2023 | 0.00 | — | — |